Merck (MRK) Stock Outlook 2026: Keytruda's Patent Cliff and the Pipeline Race

Keytruda (pembrolizumab) is one of the defining pharmaceutical achievements of the past decade. A PD-1 checkpoint inhibitor approved across more than 30 cancer indications, it generates revenues that make it one of the best-selling drugs in history. But every blockbuster eventually faces its reckoning — and for Merck, that reckoning is the 2028 Keytruda patent expiry. How Merck handles the transition is the central investment question for 2026 and beyond.

Keytruda’s Patent Cliff: Steeper or Softer Than It Looks?

The conventional narrative: Keytruda patents expire in 2028, biosimilars enter, revenue craters. The reality is more nuanced.

Biologic drugs — unlike small-molecule pills — are protected by clusters of patents covering manufacturing processes, formulations, and specific indications. Biosimilar developers must run clinical trials demonstrating comparability, then navigate FDA approval. This process takes years and introduces uncertainty.

Merck’s primary defensive strategy is the subcutaneous (SC) formulation of Keytruda. The current IV infusion requires hospital administration; a self-injected SC version would increase patient convenience and attract new patent protection. If SC Keytruda receives approval and achieves significant uptake before or alongside the IV patent cliff, it could meaningfully extend the commercial life of the franchise.

Additionally, Keytruda’s combination regimen approvals — paired with chemotherapy, other checkpoint inhibitors, or ADCs — create clinical differentiation that pure IV biosimilars cannot immediately replicate.

Related: Global Dividend Stocks Guide 2026 →

IRA Drug Price Negotiation: The Medicare Variable

The Inflation Reduction Act authorized Medicare to negotiate prices for the highest-cost drugs. Given Keytruda’s Medicare spend, it is among the most likely candidates for negotiation. A mandated price reduction in the Medicare channel would reduce Merck’s US government-payor revenues.

However, the full impact is bounded:

• International markets (Europe, Japan, China, emerging markets) are not subject to IRA
• Private commercial insurance in the US is not directly subject to IRA price caps
• The negotiated price takes effect on a schedule (check CMS for current timelines)

The net revenue impact is real but does not represent the complete Keytruda revenue base. Merck’s quarterly earnings presentations break out US vs international revenues, allowing investors to model the IRA impact more precisely.

Pipeline: What Comes After Pembrolizumab?

For Merck’s long-term investment case, the pipeline is the critical variable. Several directions are worth monitoring:

• ADC (antibody-drug conjugate) platform: Merck has made significant investments in ADC technology, which represents one of oncology’s fastest-growing categories
• Oncology combinations: Pairing Keytruda with newer agents extends clinical differentiation beyond what biosimilars can match
• Cardiometabolic pipeline: MK-0616 (an oral PCSK9 inhibitor candidate) represents a potential new franchise outside oncology
• Vaccines: Gardasil (HPV) provides stable revenue and growth in emerging markets; the RSV and pneumococcal vaccine pipeline adds optionality

Pipeline clinical status should be tracked through Merck’s quarterly pipeline updates and clinicaltrials.gov.

M&A as a Pipeline Supplement

Merck has been an active acquirer, with several billion-dollar-plus transactions completed in recent years to bolster specific pipeline areas. Strategic M&A can compress the growth gap created by the Keytruda cliff — but only if the acquired assets succeed clinically and commercially.

Watch for management commentary on capital allocation between buybacks, dividends, and M&A in earnings calls. The balance of these three shapes the MRK investment proposition.

Related: ETF vs Individual Stocks 2026 →

MRK in a US Portfolio

Merck is a classic “defensive growth” healthcare holding. Key portfolio use cases:

• 401(k)/IRA income component: Long dividend track record, quarterly payments, healthcare sector defensiveness
• Healthcare sector weighting: Provides pharmaceutical exposure with global revenue diversification
• Defensive allocation in volatile markets: Pharmaceutical revenues are relatively inelastic to economic cycles

The dividend yield should be checked at the time of investment (merck.com/investor-relations) rather than assumed from past data.

Bull and Bear Cases

Bull case

• SC Keytruda approved and widely adopted, softening the 2028 patent cliff substantially
• ADC pipeline produces multiple approved products; new revenue streams offset Keytruda decline
• IRA impact is contained; international and commercial markets cushion Medicare pricing cuts

Bear case

• SC Keytruda struggles commercially; IV biosimilars enter aggressively in 2028
• Pipeline candidates fail in Phase 3; revenue gap emerges post-cliff
• IRA negotiated prices are more punitive than expected; earnings miss

The Bottom Line

Merck in 2026 is a pharmaceutical franchise navigating from peak Keytruda toward a post-patent-cliff future that is not yet fully defined. The SC reformulation and pipeline investments are real and credible strategies, but their success is not guaranteed. Investors must assess their comfort with the 2028 transition risk and the probability that Merck’s pipeline produces enough value to maintain current earnings power. For long-term dividend investors, MRK has a strong track record — just one with a defined challenge ahead.

All financial data and pipeline details at merck.com/investor-relations. This article is informational and not investment advice.